**A feasibility study to examine discrepancy rates in pre-specified and reported outcomes in articles submitted to The BMJ.**

Jennifer Weston (Research Associate)1, Kerry Dwan (Research Associate)1 Douglas Altman (Professor)2, Mike Clarke (Professor)3, Carrol Gamble (Professor)1, Sara Schroter (Senior Researcher)4****,**** Paula Williamson (Professor) 1, Jamie Kirkham (Senior Lecturer)1\*

1 MRC North West Hub for Trials Methodology Research, Department of Biostatistics, University of Liverpool, Duncan Building Liverpool, L69 3GA, United Kingdom

2 Centre for Statistics in Medicine, University of Oxford, OX3 7LD, United Kingdom

3 All-Ireland Hub for Trials Methodology Research, Centre for Public Health, Queen's University Belfast, Belfast, BT7 1NN, United Kingdom

4 The BMJ, BMA House, Tavistock Square, London, WC1H 9JR, United Kingdom

**\*Corresponding Author:**

Dr Jamie Kirkham

Department of Biostatistics

University of Liverpool

Block F Waterhouse Building

1-5 Brownlow Street

Liverpool, L69 3GL

Email: jjk@liv.ac.uk

Tel: +44 (0) 151 794 9731

Fax: +44 (0) 151 282 4721

**[ABSTRACT](http://www.plosone.org/static/guidelines%22%20%5Cl%20%22abstract)**

**Objectives:** Adding, omitting or changing pre-specified outcomes can result in bias because it increases the potential for unacknowledged or post-hoc revisions of the planned analyses.Journals have adopted initiatives such as requiring the prospective registration of trials and the submission of study protocols to promote the transparency of reporting in clinical trials. The main objective of this feasibility study was to document the frequency and types of outcome discrepancy between pre-specified outcomes in the protocol and reported outcomes in trials submitted to The BMJ.

**Methods:** A review of all 3156 articles submitted to The BMJ between 1st September 2013 and 30th June 2014. Trial registry entries, protocols and trial reports of randomised controlled trials published by The BMJ and a random sample of those rejected were reviewed. Editorial, peer reviewer comments and author responses were also examined to ascertain any reasons for discrepancies.

**Results:** In the study period, The BMJ received 311 trial manuscripts, 21 of which were subsequently published by the journal. In trials published by The BMJ, 27% (89/333) of the pre-specified outcomes in the protocol were not reported in the submitted paper and 11% (31/275) of reported outcomes were not pre-specified. In the sample of 21 trials rejected by The BMJ, 19% (63/335) of pre-specified outcomes went unreported and 14% (45/317) of reported outcomes were not pre-specified. None of the reasons provided by published authors were suggestive of outcome reporting bias as the reasons were unrelated to the results.

**Conclusions:** Mandating the prospective registration of a trial and requesting that a protocol be uploaded when submitting a trial article to a journal has the potential to promote transparency and safeguard the evidence base against outcome reporting biases as a result of outcome discrepancies. Further guidance is needed with regards to documenting reasons for outcome discrepancies.

[**Strengths**](http://www.plosone.org/static/guidelines#abstract) **and Limitations of the Study**

* The BMJ manuscript tracking system was used to gain access to all study protocols which are often unavailable.
* The study assumed that unpublished protocols submitted to The BMJ were final versions.
* The study only described reasons for outcome discrepancies that were documented by the trial authors or questioned during peer review.
* The results were limited to trials submitted to The BMJ which may not be representative of all trials.

**INTRODUCTION**

Selective outcome reporting occurs when a subset of the originally recorded outcome variables in a trial are selectively reported in a publication based on their results. When outcome reporting is informed by the statistical significance and/or effect size (e.g., outcomes where the results are not statistically significant are not reported or reported only as p>0.05), we refer to this as outcome reporting bias [1]. This form of bias has been identified as a threat to evidence based health care because clinical trial outcomes with statistically significant results are more likely to be published [2]. As a safeguard against this form of bias, current CONSORT (Consolidating Standards of Reporting Trials) guidance recommends that completely defined primary and secondary outcome measures should be pre-specified and any changes to trial outcomes after the trial commences should be documented with reasons (CONSORT, Items 6a and 6b); and the results for each outcome should be reported for each group, and the estimated effect size and its precision (Item 17a) should also be reported [3]. Despite this guidance, empirical research has shown that statistically significant outcomes were more likely to be fully reported (where a fully reported outcome was one with sufficient data for inclusion in a systematic review meta-analysis) compared with non-significant outcomes (range of odds ratios: 2.2 to 4.7) [4]. When comparing trial publications with protocols, it was found that 40 to 62% of studies had at least one primary outcome that was changed, introduced, or omitted [4]. Previous qualitative research in this field has found that the prevalence of incomplete outcome reporting is high and researchers were generally unaware of the implications of not reporting all outcomes and protocol changes [5].

Some journals have adopted policies such as the International Committee of Medical Journal Editors (ICMJE) recommendations to deter trial authors from selectively reporting outcomes. For example, all The BMJ journals follow the recommendation that any clinical trial which commenced after 1st July 2005 will only be considered for publication if the trial was prospectively registered before the recruitment of any participants (<http://journals.bmj.com/site/authors/editorial-policies.xhtml#clinicaltrial>). The BMJ will also not consider a report of a clinical trial unless the protocol is also submitted to inform the peer review process.

The aim of this feasibility study was to gain an understanding of the practicalities of comparing pre-specified outcomes from the trial protocol and reported outcomes in the initial manuscript submission during the peer review process in order to inform a larger future study. We take a cohort of trial reports submitted to The BMJ where half of the trials were recently accepted for publication by The BMJ and half were rejected. The main objective of the study was to document the frequency and types of outcome discrepancy between pre-specified outcomes in the protocol and reported outcomes in the submitted paper. A secondary objective was to review whether these discrepancies were discussed by authors in the trial registry or manuscript, or in the case where the manuscripts underwent external peer review, during correspondence with editors and peer reviewers.

**METHODS**

***Identification of trials***

After signing a confidentiality agreement, we searched The BMJ’s manuscript tracking system to identify all reports of randomised controlled trials (RCTs) submitted to the journal between 1st September 2013 and 30th June 2014. Articles are archived after a 12 month period in the system and therefore this ten month period was chosen in order to avoid the loss of any articles between the screening and assessment stage. We included only articles that assessed the efficacy or effectiveness of a medical intervention and were submitted as the primary study publication as indicated by the trial author. If it was unclear as to whether the article was a primary publication, two experienced members of the study team (JJK and PRW) made a judgement via discussion. Secondary trial papers including cost-effectiveness analyses were excluded, since such articles are unlikely to report on all pre-specified outcomes.

The study followed a nested case control study design. From the cohort of all RCT submissions to The BMJ meeting the inclusion criteria, cases were defined to be all trials that were submitted in the chosen period and subsequently published by The BMJ. Controls consisted of a random sample (of equal size to the number that were published) of submitted and subsequently rejected articles. All rejected articles had equal chance of selection irrespective of the stage in which they were rejected, i.e. following initial screening, following external peer review or after an appeal. If a rejected article did not have a submitted protocol, then the next rejected article in the random sequence was selected until enough controls were selected.

***Trial documentation for assessment***

For each submission we downloaded the trial registry entry and the following documents from The BMJ’s manuscript tracking system: study protocol, first submission, any supplementary material, editor and peer review comments with author responses, and final published article available on ScholarOne. Trial registry entries were identified from the “Trial Registration” name and number reported as a required abstract item for RCT manuscripts submitted to The BMJ. .

***Assessment of trials and data extraction***

Using the detail from the submitted articles, we recorded trial characteristics relating to the design, conduct and size of the trial. For trials rejected by The BMJ, we recorded the main reason why the article was rejected since not all rejections are based on methodological reasons, for example, an article maybe rejected because the research question lacks novelty, relevance or importance. We also recorded whether or not the trial was prospectively/retrospectively registered according to the ICMJE definition [6], and whether or not the protocol submitted to the journal was published. In addition we recorded any outcomes-related changes with reasons that were documented in either of the historic changes and amendments section of the trial registry entries or the trial articles.

***Outcome definitions used in this study***

We defined outcomes of interest as *domains.*  An outcome *specific measurement* is the metric or tool used to support the measurement of the domain. These definitions are coherent with those used in other studies [7,8]. Some specific measurements have multiple *sub-scales*, for example, the SF-36 (Short Form-36) for measuring general health has eight health sub-scales and two summary scores (the physical and mental component summary scores). We treated each sub-scale as a separate outcome only if it was the trialists’ intention to analyse each sub-scale separately.

***Outcome comparisons and assessment***

Comparison of outcomes listed in the trial registry, the trial protocol, the initial article submission and the final published article (if available) was undertaken independently by two researchers (JW and JJK or JW and KD) to identify any similarities or discrepancies in outcome specification between the source documents. For each trial, a matrix listing the outcome domains, and specific measurements was constructed showing whether the outcome was mentioned in each of the four possible source documents. If only an outcome domain was pre-specified without reference to individual sub-scales, then this was not classed as a discrepancy if the individual outcomes were reported. For example, in rheumatology, if the disease activity index was pre-specified but the individual components of the index were reported, but not pre-specified (tender joint count, swollen joint count, patient global health and acute phase reactant) then this was not classified as a discrepancy. Similarly, a discrepancy was not declared if the specific measurement instruments used to measure outcomes were not pre-specified. For example, if quality of life was listed as a pre-specified outcome and the report used the EQ-5D to measure quality of life then this was not considered a discrepancy.

Any discrepancies between the information extracted by the two reviewers were resolved through discussion. As an additional quality control check, one author (JJK) checked all comparisons.

***Data analysis and presentation of results***

Trials were analysed and presented in accordance to whether or not they were accepted or rejected for publication by The BMJ. Inconsistencies between pre-specified outcomes (those listed in the protocol) and those reported in the initial trial report submission were documented. As a supplementary analysis, we also considered pre-specified outcomes to be those listed in the trial registry. Specific discrepancy types comprised new outcomes introduced into the trial report that were not pre-specified and pre-specified outcomes that were not mentioned in the trial report. We also noted any changes in the importance of outcomes (e.g. upgrading and downgrading pre-specified outcomes to primary and secondary outcomes respectively) and changes in measurement tools used.

For articles published by The BMJ, a review of the editorial, peer review and authors’ responses was also undertaken. We describe how often outcomes discrepancies were picked up during peer review, by whom and any reasons that were provided by the authors for the discrepancy. Outcomes that were reported in the final published manuscript were compared to those reported in the initial submission and any changes in the discrepancy rates between the protocol and initial submission and final published article reported. Any reduction in the discrepancy rate between the protocol and the final publication was seen as a crude measure of the impact of the peer review process when compared to the initial manuscript submission.

**RESULTS**

Between 1st September 2013 and 30th June 2014, 3156 research articles were submitted to The BMJ but only 10% (311/3156) of these were RCT related (Figure 1). Thirty six RCTs were excluded for reasons described in Figure 1. Of the remaining 275 RCTs, 21 (8%) were accepted for publication by The BMJ and the remaining 254 were rejected. As a requirement of publication, all accepted RCTs had an available protocol within the manuscript tracking system but authors of more than a half of the rejected RCTs (55%; 139/254) did not submit a protocol during the initial submission (Figure 1).

Characteristics of the 21 accepted trials and 21 randomly selected trials from the 115 rejected submissions with an available protocol are shown in Table 1. No trial was exclusively funded by industry and all trials were registered. Dates of trial registrations for accepted RCTs ranged from 2006-2012, for accepted protocols ranged from 1998-2013. Dates of trial registrations for rejected RCTs ranged from 2005-2012, for rejected protocols ranged from 2004-2013. A higher proportion of trials that were rejected by The BMJ were retrospectively registered and there was a tendency for more trials that were accepted by The BMJ to have a published protocol. The median number of outcomes mentioned in the source documents for trials accepted by The BMJ was 15 (range 4-42) and the median for those rejected by The BMJ was 19 (range 3-35). Sixteen of the rejected articles were rejected by the editor following initial screening, four were rejected after external peer review and one was rejected following an appeal. The decision made by the editor to reject the article was retrospective registration for five of the 21 rejected trials. Other reasons for rejection included: preliminary study/low priority for journal (6), not suitable for publication in The BMJ (5), article would be more suitable in a specialist journal (3), underpowered study (1) and premature termination of trial (1). As of April 2015, 12 of the 21 articles rejected by The BMJ have been identified as published elsewhere (Table 2).

***Outcome Discrepancies – protocol to initial manuscript submission***

In trials published by The BMJ, over a quarter of the pre-specified outcomes (27% (89/333)) in the protocol were not reported in the initial manuscript submission; 19% (63/335) in those trials that were rejected, Table 2. Eleven percent (31/275) of outcomes reported in the initial manuscript submission that were published by The BMJ were not pre-specified compared to 14% (45/317) in those trials that were rejected, Table 2. There were no discrepancies between pre-specified and reported outcomes in 19% (4/21) of trials accepted by The BMJ and 10% (2 of the 21 trials) rejected by The BMJ.

We found three instances from three separate trials (all subsequently accepted by The BMJ) where a pre-specified primary outcome was downgraded to a secondary outcome in the submitted report (Table 2). None of the trial authors specified a reason for this change although one author did amend the trial registry entry accordingly. Pre-specified secondary outcomes were not upgraded to primary outcomes in any of the submitted trial reports.

***Outcome Discrepancies – trial registry to initial manuscript submission***

Supplementary Table 1 provides the results where the trial registry was used to define the pre-specified list of outcomes. In comparison to using the protocol to define the list of pre-specified outcomes, there was a marked increase in the number of reported outcomes that were not pre-specified; 32% (87/275) for the trials accepted by The BMJ and 28% (90/317) for the trials rejected by The BMJ.

***Reasons for discrepancies***

Three rejected trial reports noted changes to outcomes in either the trial registry or protocol but did not document a reason for the change.

***Editorial impact on discrepancies (trials accepted for publication by The BMJ)***

In the 21 trials accepted by The BMJ, the editorial and peer review process raised awareness about outcome discrepancies in 82% (14/17) of the trials where there were outcome discrepancies. Editors asked authors of ten trials to make sure all registered outcomes were reported in the trial manuscript and to document any reasons for changes. The percentage of pre-specified outcomes that went unreported following peer review reduces from 27% to 21% (71/333) when substituting the initial manuscript submission for the final published article in the assessment but the percentage of outcomes that were reported but not pre-specified remained largely unchanged (11%, 32/294) (Supplementary Table 2). Editors did however request that reported outcomes that were not pre-specified were labelled as ‘post-hoc’ (five trials). In responding to peer reviewer comments, two authors suggested that qualitative and subjective outcome measures were to be reported elsewhere and in one trial there was clear evidence that the additional data had been published elsewhere. Authors also reported space limitations (despite the fact that The BMJ has no word limit for research), outcomes still being analysed and errors with updating the trial registry entry in their communications with editors as reasons for outcome discrepancies identified during the peer review process.

**DISCUSSION**

Researchers have a moral responsibility to report trial findings completely and transparently [9]. Mandating the prospective registration of a trial and requesting that a protocol be uploaded when submitting a trial article to a journal have the potential to promote transparency and reduce the incidence of outcome reporting biases as a result of outcome discrepancies. Despite these requirements, the principal findings from this study showed that, at The BMJ where these are mandated, over a quarter of pre-specified outcomes from trials that were published by The BMJ may still go unreported in submitted manuscripts reporting the primary trial results, whilst just over 10% of outcomes were newly introduced. For articles accepted by The BMJ, a review of editor, peer reviewer and author responses revealed that reasons for identified discrepancies given by trial investigators were not considered to indicate bias, since the reason for the discrepancies were unrelated to the results. There was evidence that The BMJ peer review process reduces the amount of unreported outcomes with fewer discrepancies found between the protocol and the published trial report than the initial submission. On a number of occasions, editors also requested that reported outcomes that were not pre-specified were clearly labelled as post-hoc outcomes.

***Comparison with other studies***

Two empirical studies conducted by Chan and colleagues compared the protocol and the final publication with respect to the primary outcome and concluded that 40-62% of trials had major discrepancies between the primary outcomes specified in the protocols and those defined in the published article [10,11]. Four empirical studies have found that between 13-31% of primary outcomes specified in the protocol were omitted in the publication and between 10-18% of reports introduced and outcome in the publication that was not specified in the protocol [10-13]. In one previous qualitative study, interviews were undertaken with trial investigators to discuss any discrepancies found between trial protocols and subsequent publications [5]. This interview study found that in almost all trials (15/16, 94%) in which pre-specified outcomes had been analysed at the time of primary publication but not reported, this under reporting resulted in bias. In nearly a quarter (4/17, 24%) of trials in which pre-specified outcomes had been collected but not analysed, the direction of the main findings influenced the investigators’ decision to not analyse the remaining data collected.

***Strengths and limitations***

The strength of our study rests in the use of The BMJ’s tracking system to gain access to the study protocols for each comparison. However, we did make the assumption that unpublished protocols submitted to The BMJ were finalised and no further undocumented changes were made after any outcome data were analysed. We also defined pre-specified outcomes to be those listed in the protocol since many of the rejected trials were retrospectively registered and therefore may not be truly ‘pre-specified’ outcomes, making any comparison between rejected and accepted trials unfair. Nevertheless, we acknowledge that at this time, there are no reliable, practical processes available to identify version numbers and time stamps for unpublished protocols.

A further limitation of our work is that we were only able to document reasons for outcome discrepancies that were either documented by the trial author in the source documentation or questioned during peer review. Our research uncovered many other outcome discrepancies for which the reasons are unknown. Many of these unknown reasons could be the result of outcome reporting bias. We should also be aware that over half of the authors of rejected trials that were not considered for full assessment in this study did not upload a protocol at submission. Without a protocol, a full assessment would not have been possible but also we have assumed implicitly that those rejected trials with an available protocol were not different in terms of selective reporting than those that did not submit a protocol. Furthermore, our results apply only to reports of trials submitted to The BMJ, which may not be representative of all trials; for example no industry trials are included in the sample. Selective outcome reporting and discrepancies in outcome measures has previously been identified in industry funded trials where the study protocol were supplied though litigation [14].

***Conclusions and policy implications***

There are familiar lessons from this study for trialists, journal editors and peer reviewers. Trialists must write sufficiently detailed protocols, clearly identify any amendments and new versions and adhere to them to minimise the scope for outcome reporting bias. The trial protocols supplied to The BMJ were highly variable in terms of quality, clarity and depth. For this reason, The BMJ research editors always use the publicly registered information about the trial as the main source of pre-specified outcomes. When reporting findings trialists should ensure that trial registry entries correspond to the protocol. They should describe clearly in trial reports outcomes that were measured, analysed and compared and report and explain deviations from or additions to planned outcomes. We found that none of the trial authors explained the outcome changes in the trial registry entries and submitted reports. We also found that many trial registry entries specify only outcome domains without specifying individual specific measurement tools and sub-scales which are to be used and the time points in which outcomes are to be measured. Journal editors and peer reviewers need to be able to identify all outcome discrepancies during peer review and should compare outcomes pre-specified (both primary and secondary outcomes) in the trial registry and protocol to those reported in the submitted report. Authors should be asked to make a comment on the reasons for all outcome discrepancies following peer review and journal editors should recommend that trialists upload these reasons into the trial registry entry as well as being included in the trial report. Authors should also ensure that any pre-specified outcomes not reported in the main manuscript are easily accessible if not published elsewhere.

In addition to journal editors, trial steering committee’s for individual trials can also perform a role in providing trial authors with guidance regarding outcome specification, monitoring changes in outcomes and measures and observing good practice in line with reporting standards. The SPIRIT guideline (Standard Protocol Items: Recommendations for Interventional Trials) is a valuable resource for trialists at the development stage of a trial protocol and we encourage the use of such guidelines to aid transparency of outcome selection and reporting [15].

***Future work***

Understanding the reasons for outcome discrepancies is important in order to identify what kind of mechanisms drive outcome reporting bias and also to provide guidance on how to minimise it. A larger study looking at outcome discrepancies involving more journals needs to be undertaken in order to gain insight into different journal policies using the methods outlined in this feasibility study. Owing to the problems with recall bias in the previous interview study [5], interviews with trialists during the peer review process need to be undertaken to identify the reasons for all outcome discrepancies.

**Funding**

This work was supported by the MRC Network of Hubs for Trials Methodology Research (MR/L004933/1- R47). The funders had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript of the decision to submit.

**Data sharing**

The data from this study are available from the corresponding author (jjk@liv.ac.uk). For each of the trials included in the assessment, the individual matrices displaying the outcome domains, outcomes and measurement tools that were listed and/or reported in the trial registry entry, protocol, initial manuscript submission and the final publication are available. In trials accepted by The BMJ, the editorial, peer review and author responses to all outcomes-based comments are also available.

**Author Contributions**

PRW and CG conceived the idea for the study. JJK applied for funding for the study. JJK, PRW, CG, KD, DA MC designed the study. JW downloaded all source documents from The BMJ manuscript tracking system. JW, JJK and KD carried out a comparison of the source documents. All comparisons were checked by JJK. JJK, JW, KD and PRW undertook the data analysis. All authors helped interpret the data. All authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. JJK prepared the initial manuscript. All authors commented on the final manuscript before submission. JJK is the guarantor for the project.

**Transparency declaration**

JJK affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

**Competing interests**

All authors have completed the unified competing interest form at www.icmje.org/coi\_disclosure.pdf (available on request from the corresponding author) and declare no support from any organisation for the submitted work; no financial relationships with any organisation that might have an interest in the submitted work in the previous three years; Sara Schroter is Senior Researcher at The BMJ and regularly researches the peer review process and Douglas Altman and Jamie Kirkham are statistical advisers at The BMJ. However, the authors have no other relationships or activities that could appear to have influenced the submitted work.

**Ethical approval**

No ethics committee opinion was required for this study.

**Acknowledgments**

We would like to thank Trish Groves, The BMJ Deputy editor for suggesting editorial changes to the document and providing insight into current editorial policies at The BMJ.

**References**

[1] Hutton JL, Williamson PR. Bias in meta-analysis due to outcome variable selection within studies. *Applied Statistics* (2000); **49**: 359-370.

[2] KirkhamJJ, DwanKM, Altman DG, GambleC, DoddS, SmythR, Williamson PR. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. *BMJ* 2010; **340**:c365.

[3] Schulz KF, Altman DG, Moher D et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMJ* 2010; **340**:c332.

[4] Dwan KM, Gamble C, Williamson PR, Kirkham JJ. Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias - an updated review. *PLoS ONE* 2013; **8**(7): e66844.

[5] SmythR, Kirkham JJ, JacobyA, Altman DG, Gamble C, Williamson, PR. Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists. *BMJ* 2011; 342:c7153.

[6] Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrial.gov results database—update and key issues. *New England Journal of Medicine* 2011; 364:852-60.

[7] Saldanha IJ, Dickersin K, Wang X, Li T. Outcomes in systematic reviews addressing four common eye conditions: an evaluation of completeness and comparability. *PLoS One* 2014, 9 (10): e109400. doi:10.1371/journal.pone.0109400.

[8] International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. Accessed Jan, 2016 from [www.icmje.org](http://www.icmje.org)

[9] Moher D. Reporting research results: a moral obligation for all researchers. Can. J. Anaesth. 2007;54:331-5.

[10] Chan AW, Krleza-Jeric K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health research. *CMAJ* 2004a; 171 (7): 735–740.

[11] Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical Evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. *JAMA* 2004b; 291 (20): 2457–2465.

[12] Ghersi D. Issues in the design, conduct and reporting of clinical trials that impact on the quality of decision making. Thesis (PhD.) (2006). School of Public Health, Faculty of Medicine, University of Sydney.

[13] Von Elm E, Röllin A, Blümle A, Huwiler K, Witschi M, et al. Selective reporting of outcomes of drug trials; Comparison of study protocols and published articles. *Swiss Med Wkly* (2008); 138 (13–14): 197–203.

[14] Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in industry sponsored trials of Gabapentin for off-label use. *New England Journal of Medicine.* 2009; 361: 1963-1971.

[15] [Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin J, Doré C, Parulekar W, Summerskill W, Groves T, Schulz K, Sox H, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 Statement: Defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200-207.](http://www.annals.org/article.aspx?doi=10.7326/0003-4819-158-3-201302050-00583)

**Table 1: Characteristics of randomised controlled trials included in the study**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic**  |  | Accepted by The BMJ n (%) | Rejected by The BMJ n (%) |
| Trial design:  | Parallel | 16 | (76) | 17 | (81) |
|  | Cluster | 4 | (19) | 3 | (14) |
|  | Crossover | 0 | (0) | 1 | (5) |
|  | Factorial | 1 | (5) | 0 | (0) |
| Multicentre/single centre: | Multicentre | 18 | (86) | 15 | (71) |
|  | Single centre | 3 | (14) | 6 | (29) |
| Trial sample size: | <100 | 1 | (5) | 4 | (19) |
|  | 100-999 | 14 | (67) | 13 | (62) |
|  | >1000 | 6 | (29) | 4 | (19) |
| Duration of trial (follow- up):        | <12 months        | 8 | (38) | 10 | (48) |
|  | 12 - 24 months | 12 | (57) | 9 | (43) |
|  | >24 months | 1 | (5) | 1 | (5) |
|  | Unclear | 0 | (0) | 1 | (5) |
| Location of lead investigator:  | UK | 10 | (48) | 6 | (29) |
|  | Rest of Europe | 6 | (29) | 5 | (24) |
|  | North America  | 0 | (0) | 1 | (5) |
|  | Rest of World | 5 | (24) | 9 | (43) |
| Source of funding: | Commercial | 0 | (0) | 0 | (0) |
|  | Non-commercial | 15 | (71) | 18 | (86) |
|  | Both | 5 | (24) | 3 | (14) |
|  | Not stated | 1 | (5) | 0 | (0) |
| Trial registration: | Yes | 21 | (100) | 21 | (100) |
|  | No | 0 | (0) | 0 | (0) |
| Where was the trial registered:     | Clinical trials.gov | 2 | (10) | 6 | (29) |
|  | ISRCTN Register | 16 | (76) | 9 | (43) |
|  | Australian/ New Zealand CTR | 1 | (5) | 5 | (24) |
|  | Dutch Trial RegisterUMIN CTR | 20 | (10)(0) | 01 | (0)(5) |
| Prospective/retrospective registered : | Prospective | 19 | (91) | 10 | (48) |
|  | Retrospective | 1a | (5) | 10 | (48) |
|  | Unclearb | 1 | (5) | 1 | (5) |
| Published protocol:  | Yes | 14 | (67) | 11 | (52) |
|  | No | 7 | (33) | 10 | (48) |
| Where was the protocol published:  | BMC series         | 13 | (93) | 10 | (91) |
| (n=14 accepted, n=11 rejected) | Other | 1c | (7) | 1d | (9) |
|  |  |  |  |  |  |

astudy started March 1999, prior to ICMJE trial registration recommendation

bexact date first participant recruited into trial not provided

cpublished in [Contemporary Clinical Trials](http://www.sciencedirect.com/science/journal/15517144)

dpublished in Journal of Foot and Ankle Research

BMC: BioMed Central, CTR: Clinical Trial Registry; ISRCTN: International Standard Randomised Controlled Trials Number; UMIN: University Hospital Medical Information Network

**Table 2: Outcome discrepancies between pre-specified (protocol) and reported outcomes (initial submission) from trials submitted to The BMJ**

|  |  |
| --- | --- |
| Trials accepted by The BMJ (n=21 trials) | Trials rejected by The BMJ (n=21 trials) |
|  |  | Discrepancy type |  |  | Discrepancy type |
| Article ID | Registration type | Total number of outcomes pre-specifieda | Pre-specified outcomes not reportedb | New outcomes introducedc | Total number of outcomes reportedd | Change in level of importance of an outcomee | Article ID | Registration type | Total number of outcomes pre-specifieda | Pre-specified outcomes not reportedb | New outcomes introducedc | Total number of outcomes reportedd | Change in level of importance of an outcomee |
| A1 | Prospective | 15 | 2 | 0 | 13 | 0 | R1 | Prospective | 4 | 0 | 2 | 6 | 0 |
| A3 | Prospective | 11 | 8 | 1 | 4 | 0 | R4 | Prospective | 20 | 4 | 1 | 17 | 0 |
| A4 | Prospective | 21 | 2 | 6 | 25 | (-1) | R6 | Prospective | 15 | 4 | 0 | 11 | 0 |
| A5 | Prospective | 23 | 16 | 2 | 9 | 0 | R8 | Prospective | 20 | 2 | 2 | 20 | 0 |
| A6 | Prospective | 12 | 5 | 4 | 11 | (-1) | R10 | Prospective | 22 | 0 | 2 | 24 | 0 |
| A7 | Prospective | 10 | 0 | 0 | 10 | 0 | R11 | Prospective | 30 | 19 | 3 | 14 | 0 |
| A8 | Prospective | 14 | 0 | 2 | 16 | 0 | R16 | Prospective | 5 | 1 | 0 | 4 | 0 |
| A9 | Prospective | 25 | 8 | 2 | 19 | 0 | R19 | Prospective | 11 | 5 | 11 | 17 | 0 |
| A10 | Prospective | 22 | 3 | 5 | 24 | 0 | R20 | Prospective | 15 | 0 | 1 | 16 | 0 |
| A11 | Prospective | 5 | 2 | 2 | 5 | 0 | R21 | Prospective | 3 | 0 | 0 | 3 | 0 |
| A12 | Prospective | 10 | 1 | 0 | 9 | 0 | R2 | Retrospective | 20 | 1 | 0 | 19 | 0 |
| A13 | Prospective | 3 | 0 | 0 | 3 | 0 | R3 | Retrospective | 22 | 0 | 0 | 22 | 0 |
| A14 | Prospective | 5 | 0 | 0 | 5 | 0 | R7 | Retrospective | 29 | 4 | 6 | 31 | 0 |
| A15 | Prospective | 29 | 3 | 0 | 26 | 0 | R9 | Retrospective | 15 | 7 | 0 | 8 | 0 |
| A16 | Prospective | 8 | 0 | 0 | 8 | 0 | R12 | Retrospective | 12 | 0 | 8 | 20 | 0 |
| A17 | Prospective | 22 | 0 | 2 | 24 | 0 | R13 | Retrospective | 16 | 8 | 0 | 8 | 0 |
| A19 | Prospective | 13 | 2 | 0 | 11 | 0 | R14 | Retrospective | 6 | 0 | 2 | 8 | 0 |
| A20 | Prospective | 41 | 24 | 1 | 18 | (-1) | R15 | Retrospective | 18 | 1 | 0 | 17 | 0 |
| A21 | Prospective | 21 | 1 | 0 | 20 | 0 | R17 | Retrospective | 18 | 2 | 7 | 23 | 0 |
| A18 | Retrospective | 7 | 6 | 2 | 3 | 0 | R18 | Retrospective | 15 | 2 | 0 | 13 | 0 |
| A2 | Unclear | 16 | 6 | 2 | 12 | 0 | R5 | Unclear | 19 | 3 | 0 | 16 | 0 |
| **Total** |  | 333 | 89 | 31 | 275 | (-3) | **Total** |  | 335 | 63 | 45 | 317 | 0 |
|  | Pre-specified but not reported (accept BMJ): 27% (89/333)Reported but not pre-specified (accept BMJ): 11% (31/275) |  | Pre-specified but not reported (reject BMJ): 19% (63/335)Reported but not pre-specified (reject BMJ): 14% (45/317) |

a Pre-specified: total number of outcomes listed in trial protocol.

b Outcomes mentioned in protocol but not reported on in the initial article submission.

c Outcomes not pre-specified in protocol but reported on in the initial article submission.

d Reported: total number of outcomes reported in initial submission . If only an outcome domain was specified in the protocol, all outcomes reported within this domain were counted.

e Minus (-), number of pre-specified protocol outcomes downgraded from primary to secondary outcomes in initial trial report submission; Plus (+), number of pre-specified or protocol outcomes upgraded from secondary to primary in the initial trial report submission.

**Figure 1:** **Flow diagram of research articles submitted to The BMJ (1st September 2013 to 30th June 2014).**